EC
KNSA icon

EntryPoint Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

EntryPoint Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,076
Closed -$188K – 1004
2024
Q2 		$188K Buy
+10,076
New +$189K 0.09% 435
2024
Q1 		– Sell
-1,743
Closed -$30.6K – 1592
2023
Q4 		$30.6K Buy
+1,743
New +$28.6K 0.03% 915

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

EntryPoint Capital's KNSA Position: Q3 2024 in Review

EntryPoint Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2024, closing a stake of 10,076 shares — an estimated $188K sold.

EntryPoint Capital first reported a position in KNSA in Q4 2023 and held it in 2 quarters. The position peaked at $188K in Q2 2024. 176 funds tracked by Wall St. Rank hold KNSA as of Q3 2024.

  • EntryPoint Capital reported no remaining Kiniksa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 10,076 Kiniksa Pharmaceuticals shares in Q3 2024, an estimated $188K.
  • EntryPoint Capital first reported a position in Kiniksa Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's Kiniksa Pharmaceuticals position peaked at $188K in Q2 2024.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.